Ligustrazine ferulic acid acetateAlternative Names: LFAA; Liqustrazine ferulic acid acetate
Latest Information Update: 04 Oct 2010
At a glance
- Originator Shandong University
- Developer Jiangbo Pharmaceuticals
- Class Pyrazines
- Mechanism of Action Fibrinolytic agents; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis